All starting materials except the NOTA-Bn-p-NCS that was purchased from Macrocyclics were purchased from Sigma-Aldrich (synthetic-grade) and were used without further purification. All solvents used for HPLC analysis and purification within this project were purchased from Fisher Scientific (HPLC grade). Metal-free DMSO (≥99.99995%) and MeCN (≥99.999%) were purchased from Sigma-Aldrich. Water (>18.2 MΩ cm -1 at 25 °C) was obtained from an Alpha-Q Ultrapure water system from Millipore (Bedford, MA).
Syntheses
(0.0057 mL, 0.0375 mmol) were added. The reaction mixture was stirred at room temperature for 45 min. After completion of the reaction (monitored by HPLC, 5% MeCN/H to 95% MeCN over 20 min, R t = 14.2 min, 1 mL/min) the product was purified using preparative HPLC (5% MeCN/H to 95% MeCN over 20 min, R t = 14.5 min, 8 mL/min) with purity >95%. The product was furnished as a pink solid (18.2 mg, 96% Tz-PEG 11 -NHBoc (16.3 mg, 0.0216 mmol) was dissolved in dichloromethane (DCM, 0.5 mL) before TFA (0.1 mL) was added drop wise. The resulting solution was stirred at room temperature for 30 min. The solvent was removed under reduced pressure before the deprotected product was purified via preparative HPLC (5% MeCN/H to 95% MeCN over 20 min, R t = 11.6 min, 8 mL/min) with purity >97%. The product was furnished as a pink solid (14.4 mg, 92% precursor Tz-PEG 11 -NOTA dissolved in MeCN (700 µL) was then added to the aqueous solution containing the Al-18 F complex and the resulting mixture was stirred at 90 °C for 15 min. After the given period of time the reaction vial was cooled using dry ice before the reaction mixture was diluted with water (20 mL). The obtained aqueous solution containing the labeled product was flushed through a preconditioned C18 cartridge followed by an additional 10 mL of water to remove left over [ 18 F]fluoride from the cartridge. The product [ 18 F]2 was subsequently eluted with EtOH (0.3-0.5 mL) and analyzed for purity using radio-HPLC (5% MeCN/H 2 O to 95%
MeCN over 20 min, R t = 11.5 min, 1 mL/min). Prior to each animal experiment the EtOH was removed under reduced pressure and the tracer was reconstituted in 0.9% saline for injections. In vitro stability: The radioligand was incubated with agitation (600 rpm) at 37 °C in 500 µL of either PBS or human serum. At the appropriate time points, 100 µL of the solution was transferred into a 1.7 mL centrifuge tube. In case of PBS, the aliquot was directly injected into the HPLC. For the serum samples, 100 µL of MeCN was added to the previously transferred 100 µL serum solution and the resulting solution was vortexed and centrifuged (13,000 rpm) for 5 min. The clear supernatant was removed, moved to a new centrifuge tube followed by additional centrifugation at 13,000 rpm for 5 min. The resulting clear supernatant was then used for HPLC analysis. The residual protein was checked for radioactivity, and only minimal residual radioactivity could be detected (<2%). The fraction of intact radioligand was calculated by dividing the peak area corresponding to the tracer by the integral of the entire HPLC run (5% MeCN/H 2 O to 95% MeCN over 20 min, R t = 11.5 min, 1 mL/min). The observed decomposition of the radioligand in human serum is likely related to the presence of nucleophilic sulfhydryl and amino groups in the serum that could, even at neutral pH, have a measurable negative effect on the stability of the tetrazine radioligand.
In vivo stability: A solution of the radioligand [ 18 F]2 (150 µCi in 150 µL 0.9% sterile saline) was injected into healthy athymic nude mice via the tail vein. After 1 h, 2 h and 4 h postinjection, the mice were euthanized via CO 2 asphyxiation, and the blood was removed via cardiac puncture. The blood was placed into centrifuge tubes, the radioactivity measured in a dose calibrator and then centrifuged at 13,000 rpm for 5 minutes. The serum was transferred to a new centrifuge tube and cold MeCN (100 µL) was added. The mixture was vortexed and centrifuged at 13,000 rpm for 5 minutes. The clear supernatant was transferred to another centrifuge tube, vortexed and centrifuged as described above. Subsequently, an aliquot from the clear supernatant was injected into the radio-HPLC. The residual protein from the centrifuge spins was checked for radioactivity and only minimal residual activity was found (< 3% of starting activity). The fraction of intact radioligand was calculated by dividing the peak area corresponding to the tracer by the integral of the entire HPLC run (5% MeCN/H 2 O to 95% MeCN over 20 min, R t = 11.5 min, 1 mL/min).
Click reaction of Tz-PEG 11 -Al[ 18 F]-NOTA with TCO-modified 5B1
The click reaction between the radioligand and the TCO moiety of the TCO-modified 5B1 antibody was demonstrated by incubating an equimolar amount (1.33 nmol) of the purified tracer 
Cell culture
BxPC3 cells were purchased from ATCC (Manassas, VA) and grown in RPMI modified to contain 4.5g/L glucose and 1.5g/L sodium bicarbonate and supplemented with 10% (v/v) fetal calf serum, 10mM HEPES, 1mM sodium pyruvate, 2mM L-glutamine, 10cc/L non-essential amino acids, 100IU penicillin and 100ug streptomycin.
In vivo models
All animal experiments within this study were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee of MSKCC and followed National Institutes of Health guidelines for animal welfare. Female athymic nude CrTac:NCr-Foxn1 nu mice at age 6 -8 weeks were purchased from Charles River Laboratories. For subcutaneous injections, mice were anesthetized with 2% isoflurane (Baxter Healthcare) (2 L/min medical air) before BxPC3 cells were implanted subcutaneously (5 × 10 6 cells in 150 μL 1:1 growth media/matrigel® (BD Biosciences, San Jose, CA) in the right shoulder and allowed to grow for approximately 3-4 weeks until the tumors reached 5-10 mm in size. For all intravenous injections, mice were gently warmed with a heat lamp and placed on a restrainer. The tails were sterilized with alcohol pads, and injection took place via the lateral tail vein.
Biodistribution experiments
In healthy mice and pretargeted biodistribution experiments, the radioligand Tz-PEG 11 -Al 18 F-NOTA was injected into either healthy or BxPC3-xenograft nearing mice (72 h after the injection of 5B1-TCO) via the tail vein, respectively. The organs were harvested at the appropriate time points after the animals were euthanized by CO 2 asphyxiation. The collected organs were weighed and counted in a WIZARD 2 automatic γ-counter (PerkinElmer, Boston, MA). 
Dosimetry
The pretargeted biodistribution data obtained from the utilized mouse model were first expressed as normal-organ mean standard uptake values (SUVs) versus time post-injection. It was assumed that SUVs are, in first order, independent of body mass and hence the same among species. The mean SUVs for the appropriate mouse organs were then used to calculate the mean SUVs of the same organs in a human using the organ and total-body masses of the 70kg Standard Man anatomic model. 1 These data were then corrected for radioactive decay to the time of injection and subsequently fitted to a mono-exponential or bi-exponential time-activity function, depending on the organ. This information was subsequently used to determine the organ residence times which were then entered into the OLINDA computer program to yield the mean organ absorbed doses and effective dose in rad/mCi and rem/mCi, respectively. 2 The data obtained from the herein presented 18 F-based pretargeting system were compared to the pretargeting system previously described by Viola-Villegas et al. 3 using 89 Zr-labeled 5B1 for pretargeting CA19.9 (Table S2) . Table S2 . Mean organ absorbed doses and effective dose calculated for the herein described pretargeting approach given in rad/mCi and rem/mCi, respectively, compared to the pretargeting system previously by Viola-Villegas et al. using 89 Zr-labeled 5B1 for pretargeting CA19.9.
